-
公开(公告)号：US10787441B2
公开(公告)日：2020-09-29
申请号：US16094621
申请日：2017-04-17
发明人： Joseph A. Kozlowski , Wensheng Yu , Bin Hu , Bin Zhong , Jinglai Hao , Dahai Wang , Zhixin Lei
IPC分类号： A61K31/4178 , C07D405/14 , A61K38/21 , A61K38/19 , A61K45/06
摘要： A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject.
-
2.发明授权公开(公告)号：US10738062B2
公开(公告)日：2020-08-11
申请号：US16326043
申请日：2017-08-14
发明人： Wensheng Yu , Joseph A. Kozlowski , Ling Tong , Craig A. Coburn , Bin Hu , Bin Zhong , Jinglai Hao , Dahai Wang
IPC分类号： C07D498/04 , A61K45/06 , A61K31/496 , A61K31/5365 , A61P31/14
摘要： The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
-
公开(公告)号：US09527875B2
公开(公告)日：2016-12-27
申请号：US14418147
申请日：2013-07-31
发明人： William K. Hagmann , Ravi P. Nargund , Timothy A. Blizzard , Hubert Josien , Purakkattle Biju , Christopher W. Plummer , Qun Dang , Bing Li , Derun Li , Linus S. Lin , Mingxiang Cui , Bin Hu , Jinglai Hao , Zhengxia Chen
IPC分类号： C07D417/12 , A61K31/4353 , C07F9/58 , C07D401/14 , C07D221/16 , C07D401/12 , A61K31/435 , A61K31/444 , A61K45/06 , A61K31/4412 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/496 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/675 , C07D405/12 , C07D409/14
CPC分类号： C07F9/58 , A61K31/435 , A61K31/4412 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D221/16 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/14 , C07D417/12
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译： 结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗，预防和抑制G蛋白偶联受体 受体40.本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖症和脂质疾病，例如混合或糖尿病性血脂异常，高脂血症，高胆固醇血症和 高甘油三酯血症
-
公开(公告)号：US20140371138A1
公开(公告)日：2014-12-18
申请号：US14473117
申请日：2014-08-29
发明人： Craig A. Coburn , John A. McCauley , Steven W. Ludmerer , Kun Liu , Joseph P. Vacca , Hao Wu , Bin Hu , Richard Soll , Fei Sun , Xinghai Wang , Man Yan , Chengren Zhang , Mingwei Zheng , Bin Zhong , Jian Zhu
IPC分类号： C07K5/08 , A61K38/05 , A61K38/06 , C07D471/04 , A61K31/437 , C07K5/06 , A61K45/06
CPC分类号： C07D498/04 , A61K31/4025 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/423 , A61K31/437 , A61K31/4439 , A61K31/4985 , A61K31/506 , A61K31/5365 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K38/05 , A61K38/06 , A61K45/06 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D498/10 , C07K5/06 , C07K5/08
摘要： The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
摘要翻译： 本发明涉及可用作丙型肝炎病毒（HCV）NS5A抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5A活性用于治疗或预防HCV感染的用途的式（I）化合物和 抑制基于细胞的系统中的HCV病毒复制和/或病毒生产。
-
公开(公告)号：US20220331321A1
公开(公告)日：2022-10-20
申请号：US17633655
申请日：2020-07-21
申请人： Merck Sharp & Dohme Corp. , The Walter and Eliza Hall Institute of Medical Research , MSD R & D (China) Co. LTD.
发明人： John A. McCauley , Alan F. Cowman , Manuel de Lera Ruiz , Paola Favuzza , Zhuyan Guo , Bin Hu , Michael J. Kelly, III , Zhiyu Lei , David B. Olsen , Brad Sleebs , Jennifer K. Thompson , Tony Triglia , Dongmei Zhan , Cailing Zhang , Lianyun Zhao
IPC分类号： A61K31/513 , C07D405/14 , C07D493/10 , C07D491/052 , C07D409/14 , C07D239/22 , C07D405/12 , C07D409/04 , A61P33/06 , A61K45/06
摘要： Methods of treating malaria comprising administration of compounds of Formula (I′) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
-
公开(公告)号：US10138255B2
公开(公告)日：2018-11-27
申请号：US15124635
申请日：2015-03-06
发明人： Peter D. Williams , John A. McCauley , Christopher J. Bungard , David Jonathan Bennett , Sherman T. Waddell , Gregori J. Morriello , Lehua Chang , Michael P. Dwyer , M. Katharine Holloway , Alejandro Crespo , Xin-Jie Chu , Catherine Wiscount , H. Marie Loughran , Jesse J. Manikowski , Jurgen Schulz , Kartik M. Keertikar , Bin Hu , Bin Zhong , Tao Ji
IPC分类号： A61K31/554 , C07D513/08 , A61K45/06
摘要： The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
-
公开(公告)号：US09834563B2
公开(公告)日：2017-12-05
申请号：US15039607
申请日：2014-12-17
发明人： William K. Hagmann , Bing Li , Jason W. Szewczyk , Bowei Wang , Dann Parker , Timothy Blizzard , Hubert Josien , Purakkattle Biju , Harry Chobanian , Candido Gude , Ravi P. Nargund , Barbara Pio , Qun Dang , Linus S. Lin , Bin Hu , Mingxiang Cui , Zhengxia Chen , Meibi Dai , Zaihong Zhang , Ying Lv , Lili Tian
IPC分类号： A61K31/506 , C07D493/04 , A61K45/06 , C07D213/64 , A61K31/44 , C07D409/12 , A61K31/4436 , C07D401/04 , A61K31/4545 , C07D471/04 , A61K31/437 , C07D405/12 , A61K31/4433 , C07D401/12 , A61K31/4439 , A61K31/443 , C07D239/34 , A61K31/505 , C07D451/06 , A61K31/46 , C07D221/20 , A61K31/438 , C07D213/74 , C07D417/04
CPC分类号： C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/46 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04
摘要： The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
8.发明申请HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权杂环取代的四环化合物及其用于治疗病毒性疾病的方法公开(公告)号：US20150335648A1
公开(公告)日：2015-11-26
申请号：US14761256
申请日：2013-12-31
发明人： Wensheng Yu , Ling Tong , Joseph A. Kozlowski , Oleg Selyutin , Lei Chen , Jae-Hun Kim , Deyou Sha , Razia Rizvi , Bandarpalle Shankar , Bin Hu , Bin Zhong , Dahai Wang , Jinglai Hao , Wei Wei , Tao Ji , Shuai Zan
IPC分类号： A61K31/5365 , C07D498/04 , C07D513/04 , A61K45/06
CPC分类号： A61K31/5365 , A61K31/4985 , A61K31/7056 , A61K31/7072 , A61K45/06 , C07D498/04 , C07D513/04 , Y02A50/385 , Y02A50/389 , A61K2300/00
摘要： The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
摘要翻译： 本发明涉及式（I）的新型杂环取代的四环化合物：（I）及其药学上可接受的盐，其中A，A'，R 2 R3，R4和R如本文所定义。 本发明还涉及包含至少一种杂环取代的四环化合物的组合物，以及使用杂环取代的四环化合物治疗或预防患者HCV感染的方法。
-
公开(公告)号：US10646494B2
公开(公告)日：2020-05-12
申请号：US16326039
申请日：2017-08-14
发明人： Wensheng Yu , Ling Tong , Joseph A. Kozlowski , Craig A. Coburn , De-Yi Yang , Deyou Sha , Jae-Hun Kim , Michael Dwyer , Kartik M Keertikar , Bin Hu , Bin Zhong , Jinglai Hao , Dahai Wang
IPC分类号： C07D498/04 , A61K31/5365 , C07D519/00 , C07D513/04 , A61K45/06 , A61P31/12 , A61P31/22 , A61P31/14 , A61K31/4995
摘要： The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
-
公开(公告)号：US20190127355A1
公开(公告)日：2019-05-02
申请号：US16094621
申请日：2017-04-17
发明人： Joseph A. Kozlowski , Wensheng Yu , Bin Hu , Bin Zhong , Jinglai Hao , Dahai Wang , Zhixin Lei
IPC分类号： C07D405/14 , A61K31/4178 , A61K45/06
摘要： A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject.
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.029 秒)
